Alina Drzyzga

Dr. Alina Drzyzga

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2025 in Cancers
Verified
Journal Article
Open access
PDF file
ADAlina Drzyzga
Alina Drzyzga
JCJustyna Czapla
Justyna Czapla
SMSybilla Matuszczak
Sybilla Matuszczak
BŁBarbara Łasut-Szyszka
Barbara Łasut-Szyszka
TCTomasz Cichoń
Tomasz Cichoń
RSRyszard Smolarczyk
Ryszard Smolarczyk
Background/Objectives: The stimulator of interferon genes (STING) is currently accepted as a relevant target for anti-cancer therapies. Besides encouraging results showing STING agonist-induced tumor growth inhibition, in some types of tumors the effect is less prominent. We hypothesized that higher STING levels in cancer cells and the possibility of its activation determine a greater anti-cancer response. As the local administration of STING agonists induces a systemic reaction, we emphasized the importance of host tumor-induced hematological disruption in the efficiency of the therapeutic response. Methods: We investigated the response to STING stimulation in murine cancer cell lines—melanoma (B16-F10) and breast carcinoma (4T1)—and murine normal cell lines: fibroblast cells (NIH/3T3), endothelial cells (H5V), and macrophages (J774A.1). We assessed STING agonist-induced tumor growth inhibition and the therapy’s impact on the hematological system parameters and systemic cytokine release. Results: Our results underlined the improved therapeutic effect of STING activation in melanoma (B16-F10) over breast carcinoma (4T1) tumors. The outcomes reflected a high dysregulation of the hematological system in mice with developed 4T1 tumors, which may support persistent inflammation and impede STING-induced therapeutic effects. Moreover, among typical cytokines produced following STING activation, CCL2 fold change was the one that increased the most in the serum of B16-F10-bearing mice and differentiated the observed response to the STING agonist between investigated tumor models. Conclusions: The current study provides new evidence of the different responses to STING activation among two poorly immunogenic tumor models. The high abundance of STING in B16-F10 cells and the possibility of its activation is linked with improved therapeutic response in vivo compared to 4T1. The effect also seems to be connected with a less dysregulated hematological system in mice with B16-F10 tumors over mice with 4T1 tumors. This highlighted the need for general insight into tumor-induced local and systemic responses to the efficiency of the proposed therapy.

26 February 2026 in Cancers
Verified
Journal Article
Open access
PDF file
MJMagdalena Jarosz-Biej
Magdalena Jarosz-Biej
RSRyszard Smolarczyk
Ryszard Smolarczyk
DSDorota Sprus-Lipka
Dorota Sprus-Lipka
MSMarta Szlag
Marta Szlag
ZUZbigniew Urbaś
Zbigniew Urbaś
TCTomasz Cichoń
Tomasz Cichoń
Background/Objectives: Brachytherapy (BT) is a local radiation treatment method for solid tumors. A single 10 Gy high–dose–rate (HDR) BT acts as an “in situ” vaccination. Tumor microenvironment (TME)–dependent radio–resistance mechanisms, such as increasing immunosuppression and hypoxia, lead to tumor recurrence after radiotherapy. Our study aimed to determine whether adding imiquimod (IMQ) to anticancer therapy would overcome TME–mediated mechanisms of radiotherapy resistance. IMQ, a toll–like receptor 7 (TLR7) agonist, acts as an immunostimulant and a vascular normalizing agent. Methods: Mice with well–developed tumors were treated with IMQ at a vascular–normalized dose of 50 μg, followed 5 days later by a single 10 Gy HDR BT. The dose coverage was planned using Discovery RT computed tomography CT scans. Irradiation was performed with a high–dose–rate afterloader equipped with an iridium–192 radioactive source. Results: In mice treated with a combination of IMQ and BT, we observed significant inhibition of melanoma tumor growth. We also noticed an effective therapeutic effect in mice with breast cancer, resulting in significantly prolonged survival and complete tumor regression in 20% of treated mice. In the blood of treated mice, we observed leukopenia with eosinophilia. In tumors, there was enhanced infiltration by cytotoxic CD8+ T lymphocytes. The depletion of CD8+ T cells completely abolished the effect of the combined therapy. Conclusions: The combination of IMQ with HDR brachytherapy induces a synergistic effect, improving the therapeutic antitumor effect of brachytherapy. Our data indicate that it is reasonable to use drugs that prevent changes in the TME in combination with radiotherapy.

Verified
Journal Article
Open access
PDF file
BJBartosz Jaroszewski
Bartosz Jaroszewski
MMMonika Musiał-Kulik
Monika Musiał-Kulik
RSRyszard Smolarczyk
Ryszard Smolarczyk
TCTomasz Cichoń
Tomasz Cichoń
ADAlina Drzyzga
Alina Drzyzga
Janusz KasperczykJanusz Kasperczyk
Janusz Kasperczyk
Implantable drug delivery devices may enhance therapeutic efficacy by allowing localized drug release, and they may overcome the drawbacks of conventional systemic treatment. Electrospun nanofibers are promising drug delivery systems due to their high surface-to-volume ratio, porosity, and easy drug encapsulation. However, controlled and sustained drug release is required to improve therapeutic efficacy and reduce toxicity. Also, the ability to tailor the release drug dose would be a useful tool for providing an optimal and individualized approach for the treatment. Therefore, the aim of the study was to analyze the possibility to tailor the release of paclitaxel (PTX) from poly(D,L-lactide-co-glycolide) (PDLGA) electrospun nonwovens by modifying the comonomer molar ratio. For this purpose, three kinds of polymers were compared with lactidyl-to-glycolidyl comonomer ratios of 86:14, 70:30, and 48:52. Also, nonwovens obtained from a blend of PDLGA and PVA were used to analyze the effect of the addition of the hydrophilic polymer on degradation and, thus, the release rate. The comprehensive analysis of the developed nonwovens was conducted through an evaluation of the morphology, in vitro degradation, and drug release process, as well as cytotoxicity. It has been observed that all kinds of the developed PDLGA nonwovens provide an extended-release profile but with different release rates, which depend on the comonomer unit ratio and molar mass of the copolymer. Moreover, the increase in hydrophilicity caused by PVA sufficiently accelerates PTX release. The biological activity of released PTX was confirmed under in vitro and in vivo conditions against 4T1 mouse mammary carcinoma. The results of the study enabled us to gain insight into the influence of polymer choice on PTX release from PDLGA ES implants, which may be helpful in their easier translation into the clinic and for better adjustment of the PTX dose for individual treatment.

1 February 2026 in ImmunoTargets and Therapy
Verified
Journal Article
Open access
ADAlina Drzyzga
Alina Drzyzga
JCJustyna Czapla
Justyna Czapla
TCTomasz Cichoń
Tomasz Cichoń
SMSybilla Matuszczak
Sybilla Matuszczak
EPEwelina Pilny
Ewelina Pilny
RSRyszard Smolarczyk
Ryszard Smolarczyk
The stimulator of interferon genes (STING) pathway has emerged as a promising target for cancer immunotherapy. Tumor-associated neutrophils (TANs) are underrated among the cells involved in STING-targeted therapies. The polarization state of TANs divides them into antitumor N1 and tumor-supportive N2 TANs. Our purpose was to assess whether STING activation stimulates the repolarization of TANs toward the N1 subtype and to investigate the potential participation of TANs in metastasis and macrophage polarization processes. This research was carried out on murine B16-F10 melanoma and 4T1 breast carcinomas. Flow cytometry, immunofluorescence microscopy, and multiplex immunoassay were used to assess the phenotype of TANs. Magnetic cell sorting was employed to assess the cytotoxic potential of TANs. The spontaneous 4T1 lung metastasis model enabled assessment of the impact of primary tumor targeting with STING agonist on the inhibition of metastasis and lung immune landscape changes. To verify the influence of in vivo cGAMP-activated TANs on the macrophages phenotype, the co-culture experiments of bone marrow-derived macrophages (BMDM) and TANs were conducted. In both types of tumors, STING targeting converted TANs polarization state toward anticancer N1 subtype, marked by an increase in ICAM-1, CD69, Fas, CXCL10, TNFα, CCL3 expression, and a decrease in VEGF. Targeting STING induced a cytotoxicity of TANs against 4T1 cancer cells, while neutrophils masking revealed their importance for the maintenance of health conditions. Treatment of primary 4T1 tumors resulted in inhibition of metastasis and conversion of lung immune cells toward an anticancer phenotype. Direct co-cultivation of TANs derived from cGAMP-treated tumors with BMDM polarized them toward M1-like cells. Targeting STING provides polarization of TANs phenotype toward anticancer N1 subtype. Obtained data fills the gaps in the knowledge of the impact of STING-activating therapy on TANs functions, participation in the metastasis process, and acquisition of M1 phenotype by macrophages.